Efficacy and Safety of VDPHL01 in Males With AGA

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Androgenetic AlopeciaAGAMale Pattern Baldness
Interventions
DRUG

VDPHL01

VDPHL01 Extended Release (ER) Tablet

DRUG

Placebo

Placebo

Trial Locations (44)

10075

Site 38, New York

11415

Site 37, Kew Gardens

19073

Site 08, Broomall

19462

Site 10, Plymouth Meeting

24501

Site 29, Lynchburg

29615

Site 20, Greensville

30329

Site 43, Atlanta

33021

Site 42, Hollywood

33180

Site 17, Aventura

33511

Site 25, Brandon

33613

Site 03, Tampa

35203

Site 36, Birmingham

37130

Site 16, Murfreesboro

37215

Site 04, Nashville

37909

Site 09, Knoxville

43215

Site 11, Columbus

44512

Site 39, Boardman

46250

Site 15, Indianapolis

47150

Site 32, New Albany

47906

Site 27, West Lafayette

48346

Site 26, Clarkston

55112

Site 06, New Brighton

60008

Site 23, Rolling Meadows

70006

Site 12, Metairie

70433

Site 13, Covington

70809

Site 41, Baton Rouge

72758

Site 35, Rogers

72916

Site 30, Fort Smith

75231

Site 44, Dallas

77056

Site 14, Houston

77401

Site 40, Bellaire

80109

Site 05, Castle Rock

80111

Site 24, Englewood

83704

Site 31, Boise

84095

Site 19, West Jordan

85018

Site 28, Phoenix

91403

Site 34, Sherman Oaks

92083

Site 21, Vista

92728

Site 07, Fountain Valley

94538

Site 02, Fremont

98168

Site 33, Seattle

99202

Site 01, Spokane

02135

Site 22, Brighton

07601

Site 18, Hackensack

All Listed Sponsors
lead

Veradermics, Inc.

INDUSTRY

NCT06724614 - Efficacy and Safety of VDPHL01 in Males With AGA | Biotech Hunter | Biotech Hunter